JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alfieri, A. B.
Right arrow Articles by Cubeddu, L. X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alfieri, A. B.
Right arrow Articles by Cubeddu, L. X.

Vol. 295, Issue 2, 824-829, November 2000

Nitric Oxide and NK1-Tachykinin Receptors in Cyclophosphamide-Induced Cystitis, in Rats1

Anna B. Alfieri and Luigi X. Cubeddu

Department of Pharmacology, School of Pharmacy, Central University of Venezuela, Caracas, Venezuela (A.B.A., L.X.C.); and Nova Southeastern University, Health Profession Division, Ft. Lauderdale, Florida (L.X.C.)

The present study was conducted to investigate the role of NK1 receptors and of nitric oxide (NO) on the pathogenesis of cyclophosphamide-induced cystitis, in rats. This bladder toxicity was characterized by marked increases in protein plasma extravasation, urothelial damage, edema, white blood cell infiltrates, and vascular congestion. These changes were associated with appearance of Ca2+-independent NO-synthase (NOS) activity [characteristic of inducible NOS (iNOS)] in the bladder and with increases in urinary NO metabolites. GR205171, a selective NK1 antagonist (10-20 mg/kg, i.p.) reduced cyclophosphamide-induced increases in protein plasma extravasation and in the urinary excretion of NO metabolites. NG-Nitro-L-arginine (L-NNA) (10 mg/kg, i.p.), a NOS inhibitor, reduced basal and cyclophosphamide-induced increases in NO metabolites and protected against cyclophosphamide-induced protein plasma extravasation. GR205171 had no effect, whereas L-NNA reduced basal NO metabolite excretion. Combined treatment with the NK1 antagonist and the NO-synthesis inhibitor produced comparable reduction in protein plasma extravasation than that achieved with each drug given separately. Combined drug treatment ameliorated cyclophosphamideinduced urothelial damage, and the extent of edema, vascular congestion, and white blood cell infiltrates in the bladder. In summary, NK1 receptors and iNOS play a role in NO formation and on cyclophosphamide-induced cystitis. Activation of NK1 receptors mainly acts through the formation of NO. It is proposed that cyclophosphamide and/or its metabolites would stimulate primary afferent capsaicin-sensitive fibers in the bladder, releasing neuropeptides, which would activate NK1 receptors. However, additional mechanisms are involved, because neither the NK1 receptor antagonist nor the NO synthesis inhibitor, either alone or in combination, were able to completely prevent the toxicity.


1 This study was supported by a grant from the Consejo de Desarrollo Cientifico y Humanistico of the Central University of Venezuela (CDCH 06.10.3509.95) and by a grant from the CONICIT (S1-96001890).


0022-3565/00/2952-0824$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.